SWAV / Should You Buy ShockWave Medical (SWAV) Ahead of Earnings?

ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

After reaching an important support level, Shockwave Medical (SWAV) could be a good stock pick from a technical perspective. SWAV surpassed resistance more_horizontal

SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of t more_horizontal

Shockwave Medical Inc. is a medical device developer focusing on calcified cardiovascular disease treatments, with a promising market opportunity. SWA more_horizontal

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launch more_horizontal

Shockwave Medical's Q2 results exceeded revenue expectations but fell short on earnings. The bottom-line shortfall came amid acquisition expenses and more_horizontal

Shockwave Medical (SWAV) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares t more_horizontal

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies. more_horizontal